2-Amino-5-[(4,5-dihydroxy-4-methylimidazolidin-2-ylidene)amino]pentanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Amino-5-[(4,5-dihydroxy-4-methylimidazolidin-2-ylidene)amino]pentanamide
• 英文别名: 2-amino-5-[(4,5-dihydroxy-4-methylimidazolidin-2-ylidene)amino]pentanamide
• 化学式: C₉H₁₉N₅O₃
• 分子量: 245.28
• InChiKey: ONVLFEKZWUCNLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  146
• 氢给体数：
  6
• 氢受体数：
  5

文献信息

• US20140275486A1
  申请人：——

  公开号：US20140275486A1

  公开（公告）日：2014-09-18
• HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME
  申请人：ABBVIE INC.

  公开号：US20150045542A1

  公开（公告）日：2015-02-12

  Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
• Human Antibodies that Bind Human TNF-Alpha and Methods of Preparing the Same
  申请人：AbbVie Inc.

  公开号：US20170029495A1

  公开（公告）日：2017-02-02

  Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
• US9193787B2
  申请人：——

  公开号：US9193787B2

  公开（公告）日：2015-11-24
• US9505833B2
  申请人：——

  公开号：US9505833B2

  公开（公告）日：2016-11-29